Conventus Orthopaedics Secures $20 Million Series C Funding to Advance Commercialization of Conventus Cage for Limb Fracture Repair

VCBeat (WeChat: vcbeat) has learned that Conventus Orthopaedics, a medical device company dedicated to revolutionizing the treatment of extremity fractures, announced on May 9 the completion of a $20 million Series C equity financing round. The round was led by Deerfield Management, with funding provided entirely by a consortium owned by the company. This brings Conventus’ total cumulative financing to $78.93 million.

Conventus Orthopaedics Historical Financing Data

The funds from this round of financing will be used to advance its Conventus Cage implant, designed for three-dimensional fixation and fracture repair. As early as November 2015, the company raised $23.43 million to support this Cage technology. The $20 million obtained in this round will primarily be used to commercialize treatments for proximal humerus fracture repair and to further develop the product.

The Conventus Cage 3D Fracture Management System is an intramedullary implant designed for the repair of extremity fractures, enabling surgeons to effectively treat various periarticular fractures with minimal surgical trauma. The FDA has currently approved its use for treating fractures of the shoulder, elbow, and wrist. This approach, which preserves soft tissue and blood supply, allows patients to recover earlier and experience less pain compared to traditional fracture treatments.

Compared with historical literature on existing fracture repair methods, the Cage has consistently demonstrated favorable early clinical outcomes in patients. This technology provides more stable fracture fixation, leading to faster recovery, reduced pain, improved range of motion, and fewer surgical complications. The Conventus Cage enables treatmentProximal Humerus，Distal RadiusandProximal Radius Fracturethree-dimensional fixation is less invasive and more reliable.

For instance, proximal humeral fractures remain a challenge for orthopedic surgeons, as no specific repair technique or method has been proven superior in the clinical literature. Inaccurate anatomical reduction, compromised medial column support, and low bone mineral density are the primary factors contributing to treatment failure in these patients. Conventus Medical’s Proximal Humerus Cage (PH Cage) represents an industry-first alternative designed to directly address these failure modes by providing a novel technology for intramedullary supportive fixation.

The Cage provides direct medial column support by placing specially designed structural components within the intramedullary space and anchoring the device to the humeral diaphyseal column. This approach is analogous to the use of fibular struts and other materials to address medial column support in humeral fractures. The PH Cage creates a rigid intramedullary scaffold to increase bone density and provides subchondral support that allows for multi-axial screw placement. The PH Cage re-establishes cortical-like fixation within osteoporotic bone and provides the pull-out strength necessary for robust repair. Leveraging the shape-memory properties of Nitinol, the PH Cage can be collapsed and delivered through a small cannula, then expanded within the bone to form a solid fixation that helps prevent head collapse. The Cage is available in shapes and sizes tailored to each patient and can be removed if necessary.

Conventus Orthopaedics is an early-stage company founded in 2009, headquartered in Maple Grove, Minnesota, USA. The company comprises a team of medical device professionals and physicians dedicated to developing minimally invasive solutions for intra-articular and periarticular fractures.

Its team of physicians primarily specializes in professional orthopedic surgery, reconstructive surgery, spinal surgery, joint replacement, sports medicine, physical therapy, and surgical care for fractures, arthritis, strains, sprains, and sports-related injuries. Conventus’s proprietary Cage technology is designed to improve patient recovery outcomes, enhance the surgeon experience, and deliver economic value to stakeholders in this market.

The founding team of Conventus Orthopaedics, including Chief Business Officer David Blue, Chief Financial Officer John Feriancek, Vice President of R&D Michael Brenzel, and Vice President of Quality Regulatory and Clinical Affairs Kent Lind, all possess strong medical backgrounds and over 20 years of industry experience. For instance, Kent Lind, the company’s Vice President of Clinical Affairs, has more than 25 years of experience in the medical device sector and holds a Bachelor of Science degree in Industrial Engineering from St. Cloud State University. He has conducted regulatory, quality, and clinical work for newly developed products in cardiology, gastroenterology, and urology, having previously worked at St. Jude Medical, Torax Medical, Sinus Rhythm Technologies, and Urologix. Most recently, Kent served as Vice President of Quality and Regulatory Affairs at Torax Medical, where he was responsible for defining and executing clinical and regulatory submissions (to regulatory authorities, ethics committees, CE marking, IDE/PMA) as well as defining and implementing quality systems.

Regarding this financing round, Scott Flora, CEO of Conventus, stated in a press release: “The Conventus Cage is the future of fracture repair. We are delighted that our lead investor, Deerfield Management, shares this vision and continues to provide long-term financial support to realize the full potential of this technology.”

Avi Kometz, Managing Partner at Deerfield, also stated in his prepared remarks: “Conventus Cage is a truly innovative technology poised to disrupt the orthopedic trauma market. Its early clinical results have been outstanding, guiding our continued long-term investment in the company.”